# Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS

> **NCT04485065** · PHASE1 · SUSPENDED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** IBI188+azacitidine

## Key facts

- **NCT ID:** NCT04485065
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-09-30
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-08-20
- **Target enrollment:** 120 (ESTIMATED)
- **Why stopped:** Suspended for changes in development strategy
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04485065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04485065, "Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04485065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*